Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and glofitamab (glofit) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)

被引：0
|
作者：
Locke, F. L. [1 ]
Chen, J. M. [2 ]
Chan, K. [2 ]
Ray, M. D. [3 ]
Zhang, I. [4 ]
Keeping, S.
Fu, C. [5 ]
Patel, A. R. [3 ]
Oluwole, O. O. [6 ]
机构：
[1] Univ S Florida, Blood & Marrow Transplant & Cellular Immunother, H Lee Moffitt Canc Ctr, Tampa, FL USA
[2] PRECISIONheor, Evidence Synth, Vancouver, BC, Canada
[3] Gilead Co, Hlth Econ Outcomes Res, Kite, Santa Monica, CA USA
[4] PRECISIONheor, Evidence Synth, Oak- Iand, CA USA
[5] Gilead Co, US Med Affairs, Kite, Santa Monica, CA USA
[6] Vanderbilt Univ, Hematol Oncol, Med Ctr, Nashville, TN USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.703
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
839P
引用
收藏
页码：S549 / S549
页数：1
相关论文
共 50 条
  • [21] Health Utilities for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL): Ad Hoc Analysis From an Axicabtagene Ciloleucel (Axi-cel) Safety Management Study
    Lin, Vincent W.
    Jiang, Yizhou
    Chuang, Ling Hsiang
    Navale, Lynn
    Cheng, Paul
    Purdum, Anna
    BONE MARROW TRANSPLANTATION, 2018, 53 : 879 - 879
  • [22] Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Lee, Dasom
    Kambhampati, Swetha
    Bobillo, Maria Silvina Odstrcil
    Adedokun, Babatunde
    Shadman, Mazyar
    Olson, Amanda L.
    Herrera, Alex F.
    Lee, Catherine J.
    Jacobson, Caron A.
    Bye, Matthew
    Hamadani, Mehdi
    Kim, Soyoung
    Dahiya, Saurabh
    Hu, Zhen-Huan
    Speth, Kelly
    To, Christina
    Mirjah, Debbie L.
    Best, Timothy
    Locke, Frederick L.
    Ahmed, Nausheen
    Tees, Michael T.
    Pasquini, Marcelo C.
    Ahmed, Sairah
    BLOOD, 2024, 144 : 527 - 528
  • [23] ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)
    Kenderian, Saad S.
    Oluwole, Olalekan O.
    McCarthy, Philip L.
    Reshef, Ran
    Shiraz, Parveen
    Ahmed, Omar
    Le Gall, John
    Nahas, Myrna
    Tang, Lily
    Neelapu, Sattva S.
    BLOOD, 2020, 136
  • [24] Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    Nastoupil, Loretta J.
    Bonner, Ashley
    Wang, Pearl
    Almuallem, Lamees
    Desai, Jigar
    Fasan, Omotayo
    Farazi, Thalia
    Kumar, Jinender
    Dahiya, Saurabh
    BLOOD, 2023, 142
  • [25] Primary Analysis of ZUMA7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) versus StandardofCare (SOC) Therapy in Patients (Pts) with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Ghobadi, Armin
    Locke, Frederick L.
    Miklos, David B.
    Jacobson, Caron A.
    Perales, Miguel-Angel
    Kersten, Marie Jose
    Oluwole, Olalekan O.
    Rapoport, Aaron P.
    McGuirk, Joseph P.
    Pagel, John M.
    Munoz, Javier
    Farooq, Umar
    van Meerten, Tom
    Reagan, Patrick M.
    Sureda, Anna
    Flinn, Ian W.
    Vandenberghe, Peter
    Song, Kevin W.
    Dickinson, Michael
    Minnema, Monique C.
    Riedell, Peter A.
    Leslie, Lori A.
    Chaganti, Sridhar
    Yang, Yin
    Filosto, Simone
    Schupp, Marco
    To, Christina
    Cheng, Paul
    Gordon, Leo I.
    Westin, Jason R.
    MOLECULAR THERAPY, 2022, 30 (04) : 519 - 519
  • [26] Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
    Bharadwaj, Sushma
    Lau, Eric
    Goyal, Anmol
    Hamilton, Mark P.
    Srinagesh, Hrishikesh
    Jensen, Alexandria
    Syal, Shriya
    Mallampet, Jayasindhu
    Latchford, Theresa
    Sahaf, Bita
    Weng, Wen-Kai
    Smith, Melody
    Maecker, Holden T.
    Frank, Matthew J.
    Miklos, David B.
    Dahiya, Saurabh
    BLOOD, 2023, 142
  • [27] Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
    Lunning, Matthew A.
    Wang, Hai-Lin
    Hu, Zhen-Huan
    Locke, Frederick L.
    Siddiqi, Tanya
    Jacobson, Caron A.
    Ahmed, Sairah
    Miklos, David B.
    Lin, Yi
    Hill, Brian T.
    Ghobadi, Armin
    Neelapu, Sattva S.
    Westin, Jason
    Miao, Harry
    Shahani, Shilpa
    Patel, Anik R.
    Spooner, Clare
    Fu, Christine
    Xu, Hairong
    Pasquini, Marcelo C.
    BLOOD, 2022, 140 : 1852 - 1855
  • [28] Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
    Bharadwaj, Sushma
    Lau, Eric
    Hashmi, Ayesha
    Hamilton, Mark P.
    Jensen, Alexandria
    Goyal, Anmol
    Marar, Mallika
    Lee, Caroline
    Ananth, Snegha
    Sahaf, Bita
    Mallampet, Jayasindhu
    Ehlinger, Zachary
    Syal, Shriya
    Patil, Sunita
    Guo, Henry
    Smith, Melody
    Weng, Wen-Kai
    Frank, Matthew J.
    Binkley, Michael S.
    Miklos, David B.
    Dahiya, Saurabh
    BLOOD, 2023, 142
  • [29] Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Chaganti, Sridhar
    Cwynarski, Kate
    Cunningham, David
    Locke, Frederick L.
    Miklos, David B.
    Jacobson, Caron A.
    Perales, Miguel-Angel
    Kersten, Marie Jose
    Oluwole, Olalekan O.
    Ghobadi, Armin
    Rapoport, Aaron P.
    McGuirk, Joseph P.
    Pagel, John M.
    Munoz, Javier
    Farooq, Umar
    van Meerten, Tom
    Reagan, Patrick M.
    Sureda, Anna
    Flinn, Ian W.
    Vandenberghe, Peter
    Song, Kevin W.
    Dickinson, Michael
    Minnema, Monique C.
    Riedell, Peter A.
    Leslie, Lori A.
    Yang, Yin
    Filosto, Simone
    Schupp, Marco
    To, Christina
    Cheng, Paul
    Gordon, Leo I.
    Radford, John
    Westin, Jason R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 20 - 22
  • [30] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
    Oluwole, Olalekan O.
    Forcade, Edouard
    Munoz, Javier
    de Guibert, Sophie
    Vose, Julie M.
    Bartlett, Nancy L.
    Lin, Yi
    Deol, Abhinav
    McSweeney, Peter A.
    Goy, Andre H.
    Kersten, Marie Jose
    Jacobson, Caron A.
    Farooq, Umar
    Minnema, Monique C.
    Thieblemont, Catherine
    Timmerman, John
    Stiff, Patrick
    Avivi, Irit
    Tzachanis, Dimitrios
    Zheng, Yan
    Vardhanabhuti, Saran
    Nater, Jenny
    Shen, Rhine R.
    Miao, Harry
    Kim, Jenny
    van Meerten, Tom
    BLOOD, 2022, 140 : 10399 - 10401
12345